Social, emotional and mental wellbeing in primary and secondary education
In development [GID-NG10125] Expected publication date: 06 July 2022
Search results
480 results
-
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Sebelipase alfa for treating Wolman disease [ID3995]
In development [GID-HST10047] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-HST10044] Expected publication date: 25 January 2023
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
In development [GID-HST10034] Expected publication date: 20 July 2022
-
Onasemnogene abeparvovec for treating spinal muscular atrophy (review of HST15) [ID4051]
In development [GID-HST10053] Expected publication date: TBC
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
In development [GID-HST10052] Expected publication date: 29 March 2023
-
Alcohol-use disorders: prevention (update)
In development [GID-NG10299] Expected publication date: TBC
-
Managing common infections - antimicrobial prescribing guidelines
In development [GID-NG10050] Expected publication date: TBC
-
Mental wellbeing in over 65s: occupational therapy and physical activity interventions
In development [GID-NG10309] Expected publication date: 30 November 2022
-
Reducing sexually transmitted infections
In development [GID-NG10142] Expected publication date: 15 June 2022
-
Tobacco: preventing uptake, promoting quitting and treating dependence (additional update)
In development [GID-NG10271] Expected publication date: 04 August 2022
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal [TA714] Published: 14 July 2021
-
Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]
Technology appraisal [TA560] Published: 20 February 2019
-
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal [TA582] Published: 24 May 2019
-
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
In development [GID-TA10764] Expected publication date: TBC
-
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
In development [GID-TA10596] Expected publication date: TBC
-
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]
In development [GID-TA10664] Expected publication date: TBC
-
Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]
In development [GID-TA10653] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]
In development [GID-TA10186] Expected publication date: TBC
-
Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]
In development [GID-TAG363] Expected publication date: TBC
-
Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]
In development [GID-TAG494] Expected publication date: TBC
-
KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
In development [GID-TA10316] Expected publication date: TBC
-
Diabetes - buccal insulin [ID311]
In development [GID-TAG244] Expected publication date: TBC
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC
-
Dapagliflozin for treating heart failure with preserved ejection fraction ID1648
In development [GID-TA10942] Expected publication date: TBC
-
Ranibizumab port delivery system for treating wet age-related macular degeneration [ID3983]
In development [GID-TA10879] Expected publication date: TBC
-
Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]
In development [GID-TA10792] Expected publication date: 14 September 2022
-
Tofacitinib for treating active ankylosing spondylitis [ID3865]
In development [GID-TA10771] Expected publication date: 17 August 2022
-
Upadacitinib for treating active ankylosing spondylitis [ID3848]
In development [GID-TA10735] Expected publication date: 17 August 2022
-
Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]
In development [GID-TA10671] Expected publication date: 25 January 2023
-
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]
In development [GID-TA10751] Expected publication date: 13 July 2022
-
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
In development [GID-TA10311] Expected publication date: TBC
-
Mobocertinib for treating EGFR Exon 20 insertion-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3984]
In development [GID-TA10881] Expected publication date: 12 October 2022
-
Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy [ID3836]
In development [GID-TA10729] Expected publication date: 12 October 2022
-
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
In development [GID-TA10886] Expected publication date: TBC
-
Empagliflozin for treating chronic heart failure with preserved ejection fraction [ID3945]
In development [GID-TA10946] Expected publication date: TBC
-
Eptinezumab for preventing migraine [ID3803]
In development [GID-TA10677] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
In development [GID-TA10786] Expected publication date: TBC
-
Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma [ID2712]
In development [GID-TA10572] Expected publication date: 23 November 2022
-
Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
In development [GID-TA10878] Expected publication date: 25 January 2023
-
Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]
In development [GID-TA10742] Expected publication date: 10 August 2022